Venture Funding Deals: Gene Editing Attracts Big Investors, Roivant Sets Financing Record

In the largest private biopharma round to date, Roivant raises $1.1bn to fund new subsidiaries. The next highest round in August was for gene-editing-focused Homology Medicines.